Ardelyx Pharma - ARDX Earnings per share for the last 12 months

Official company branding of Ardelyx Inc (ARDX)

Ardelyx, Inc. (ARDX) is a defensive asset whose income is independent of macroeconomic conditions. Growth is driven by partnerships with global distributors to promote Xphozah. The annual EPS TTM trend captures the current trajectory, where the current value equals 4.70. Ardelyx, Inc. (ARDX) is implementing a unique therapy for cardiorenal pathologies by blocking specific intestinal receptors to treat kidney disease.

ARDX: Ardelyx Pharma Net earnings per share (EPS TTM) 02/11/2024 - 11/17/2026

Ardelyx Corp - analytical breakdowns and key metrics (ARDX)

- market price and analyst price targets:
Initial company analysis:Ardelyx ARDX
Core merchandise of Ardelyx Pharma

This indicator measures the dynamics of net earnings per share over the last 12 months relative to the same period last year, capturing the business scaling rates. The current value of 4.70 reflects the financial impact of high physician and patient confidence following FDA approval, making the annual EPS growth rate over the last 12 months a key confirmation of the capitalization of Ardelyx, Inc. (ARDX) reputational success.